Biolexis Therapeutics
Biolexis is a pioneering biotechnology company dedicated to accelerating human longevity through scientific research and innovative drug development. Focused on metabolic and chronic inflammatory solutions, Biolexis aims to create effective, easily administered, and economically viable treatments to improve healthspan and address diseases such as obesity, diabetes, heart disease, and dementia. With a proprietary AI-driven discovery engine, the company is advancing multiple therapies, including anti-obesity drugs and longevity-focused compounds, into clinical trials.
Industries
Nr. of Employees
small (1-50)
Biolexis Therapeutics
American Fork, Utah, United States, North America
Products
Clinical-stage oral anti-obesity small-molecule candidates
A set of orally administered small-molecule programs targeting metabolic pathways, with multiple candidates planned to enter first-in-human clinical trials.
Isoform-specific AMPK activator programs
Preclinical small-molecule agonists selective for AMPK isoforms intended to address weight loss and metabolic health.
Clinical-stage oral anti-obesity small-molecule candidates
A set of orally administered small-molecule programs targeting metabolic pathways, with multiple candidates planned to enter first-in-human clinical trials.
Isoform-specific AMPK activator programs
Preclinical small-molecule agonists selective for AMPK isoforms intended to address weight loss and metabolic health.
Services
End-to-end small-molecule drug discovery and development
Integrated discovery, preclinical development, IND-enabling studies, and progression to first-in-human clinical trials for metabolic disease candidates.
End-to-end small-molecule drug discovery and development
Integrated discovery, preclinical development, IND-enabling studies, and progression to first-in-human clinical trials for metabolic disease candidates.
Expertise Areas
- AI-driven drug discovery
- Oral small-molecule drug discovery
- Metabolic and obesity therapeutics
- Preclinical pharmacology and animal models
Key Technologies
- AI-driven computational chemistry and discovery
- Oral small-molecule therapeutics
- GLP-1 receptor modulation
- Isoform-selective AMPK activation